• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

前列腺组织学系列检查:激素治疗反应的有效标志物

Serial prostatic histology. A valid marker of response to hormone treatment.

作者信息

Bishop M C, Ansell I D, Taylor M C, Thomas A L

出版信息

Br J Urol. 1985 Aug;57(4):453-7. doi: 10.1111/j.1464-410x.1985.tb06309.x.

DOI:10.1111/j.1464-410x.1985.tb06309.x
PMID:3896369
Abstract

Serial transrectal needle biopsies were taken from 146 patients (657 specimens) with advanced prostatic cancer (T3/T4, M1/MO) admitted to a trial of two forms of oestrogen therapy. Histological grading by Gleason and Mostofi techniques on the initial biopsy showed no correlation either with extent of disease or its eventual outcome on treatment. Change in grade was dissociated from the response of bone metastases to hormone treatment and did not appear to influence survival. However, the prognosis of 16 patients showing clearance of tumour from their serial biopsies was generally good.

摘要

对146例(657份标本)晚期前列腺癌(T3/T4,M1/M0)患者进行了系列经直肠针吸活检,这些患者参加了两种雌激素治疗形式的试验。初次活检时采用Gleason和Mostofi技术进行的组织学分级与疾病范围或其最终治疗结果均无相关性。分级变化与骨转移对激素治疗的反应无关,似乎也不影响生存率。然而,16例系列活检显示肿瘤清除的患者预后总体良好。

相似文献

1
Serial prostatic histology. A valid marker of response to hormone treatment.前列腺组织学系列检查:激素治疗反应的有效标志物
Br J Urol. 1985 Aug;57(4):453-7. doi: 10.1111/j.1464-410x.1985.tb06309.x.
2
A comparison of the effect of diethylstilbestrol with low dose estramustine phosphate in the treatment of advanced prostatic cancer: final analysis of a phase III trial of the European Organization for Research on Treatment of Cancer.
J Urol. 1986 Sep;136(3):619-23. doi: 10.1016/s0022-5347(17)44995-0.
3
Estramustine phosphate in prostate cancer. EORTC experience: preliminary results of Protocol 30762.
Urology. 1984 Jun;23(6 Suppl):64-8. doi: 10.1016/s0090-4295(84)80101-6.
4
Estramustine phosphate as primary therapy for metastatic prostate cancer. Preliminary results of the University of Wisconsin trial.
Urology. 1984 Jun;23(6 Suppl):69-72. doi: 10.1016/s0090-4295(84)80102-8.
5
Plasma hormone levels in patients with prostatic carcinoma treated with diethylstilboestrol and estramustine.
Br J Urol. 1985 Oct;57(5):542-7. doi: 10.1111/j.1464-410x.1985.tb05863.x.
6
The treatment of disseminated prostate cancer with estramustine.
Aust N Z J Surg. 1992 Nov;62(11):871-3. doi: 10.1111/j.1445-2197.1992.tb06942.x.
7
Combined hormono/chemotherapy as primary treatment for metastatic prostate cancer: a randomized, multicenter study of orchiectomy alone versus orchiectomy plus estramustine phosphate. The Dutch Estracyt Study Group.联合激素/化疗作为转移性前列腺癌的一线治疗:单纯睾丸切除术与睾丸切除术加磷酸雌莫司汀的随机、多中心研究。荷兰雌莫司汀研究组
Urology. 1997 Mar;49(3):411-20. doi: 10.1016/s0090-4295(96)00496-7.
8
Estramustine phosphate vs diethylstilbestrol in the treatment of stage D prostate cancer.
Prog Clin Biol Res. 1989;303:177-86.
9
Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer.口服雌莫司汀、口服依托泊苷和静脉注射紫杉醇用于激素难治性前列腺癌的II期试验。
J Clin Oncol. 1999 Jun;17(6):1664-71. doi: 10.1200/JCO.1999.17.6.1664.
10
Impact of pretreatment factors, biopsy Gleason grade volume indices and post-treatment nadir PSA on overall survival in patients with metastatic prostate cancer treated with step-up hormonal therapy.在接受逐步激素治疗的转移性前列腺癌患者中,预处理因素、活检 Gleason 分级体积指数和治疗后 PSA 最低值对总生存的影响。
Prostate Cancer Prostatic Dis. 2012 Mar;15(1):75-86. doi: 10.1038/pcan.2011.47. Epub 2011 Oct 11.